The phase III study of Odivo Assisted Therapy III after esophageal cancer and gastroesophageal connecting cancer reached the main endpoint.

Guide: Odevo is the first and only treatment to be shown to be effective in patients with esophageal cancer and gastroesophageal connecting cancer who have underwent new assisted chemotherapy and surgical removal.
. Esophageal cancer and gastroesophageal connectivity cancer postoperative Odivo (Navulyu monoanti) auxiliary treatment Phase III clinical study CheckMate-577 reached the main endpoint disease-free survival Odivo is the first and currently the only patients with new assisted chemotherapy and surgical removal of esophageal cancer and gastroesophageal connecting cancer has been shown to be effective after melanoma. Tube cancer and gastroesophageal connectivity cancer are the second tumors that Odivo's complementary treatment has been shown to benefit from.
the study was designed to assess the effectiveness of Odivo (Navulyu monoanti) as an auxiliary treatment for patients with esophageal cancer and gastroesophageal connecting cancers.
study showed that patients with Odivo's new assisted chemotherapy (CRT) and surgical excision showed significant statistically significant advantages in the main study endpoint DFS compared to placebo, and that different types of patients in the group benefited.
in this study, Odivo's safety is consistent with previous studies.
after melanoma, esophageal cancer and gastroesophageal cancer became the second tumor that Odivo has been shown to benefit from as an auxiliary treatment.
50 percent of patients with esophageal cancer and gastroesophageal cancer who undergo surgery to remove the tumor after undergoing new assisted chemotherapy will still relapse within four years.
, patients who do not achieve full remission after the new complementary treatment will relapse in a shorter period of time.
"Dr. Ronan J. Kelly, Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, said, "The treatment options available to oncologists are very limited for patients who undergo surgery to remove the tumor after undergoing new assisted chemotherapy but do not receive complete pathological remission."
is expected to be the first complementary treatment for such patients.
" Odivo is the first and only treatment that can help patients with esophageal and gastroesophageal cancer improve disease-free survival and safe and controlled after new assisted chemotherapy and surgery. Dr. Ian M. Waxman, Head of Research and Development, Gastrointestinal Cancer Group,
", said, "The Findings of CheckMate-577 are critical to this type of doctor and patient, demonstrating that Odivo is expected to be a new standard treatment for patients with esophageal cancer and gastroesophageal connectivity who undergo surgery after new assisted chemotherapy.
we plan to make research data available to health authorities around the world so that Odivo can benefit patients with urgent treatment needs as an ancillary treatment as early as possible.
" Shishi Shiguibao will complete a comprehensive assessment of the existing data from the CheckMate-577 study and work with the researchers to present the results at an academic conference in the near future.
, the company will also discuss the study and its results with the health administration.
CheckMate-577 study will continue as planned, and data, including the Total Lifetime (OS) of secondary endpoints, will be analyzed at a later date.
. Navuliyu monoantigen has not yet been approved in Chinese mainland esophageal cancer and melanoma adaptation certificate For CheckMate-577 study CheckMate-577 is a Phase III, randomized, multi-center, double-blind clinical study designed to evaluate the efficacy of esophageal cancer and gastroesophageal connecting cancer patients who have not been fully remissioned after surgery for new assisted radiotherapy (CRT).
end of the study was disease-free lifetime (DFS) and the secondary endpoint was total lifetime (OS).
After receiving new assisted chemotherapy and a complete tumor excision, patients were randomly assigned to the placebo group or Odivo group, Odivo group patients received Odivo 240 mg, every 2 weeks intravenous drips, after 16 weeks of continuous use, sequentia Odivo 480 mg, every 4 weeks intravenous injections, until the disease progresses or there is intositable toxicity.
about esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of cancer death.
squamous cell carcinoma and adenocarcinoma are the two most common types, accounting for nearly 84% and 15% of the total number of esophageal cancer patients, respectively, but the histological characteristics of esophageal cancer vary by region.
, esophageal cancer is the sixth most common cancer and the fourth leading cause of cancer death, after lung, stomach and liver cancers.
most people with esophageal cancer are diagnosed with advanced stages and their daily lives, including their diet, are affected.
about stomach cancer and gastroesophageal cancer is the fifth most common cancer in the world and the third leading cause of cancer death.
broad definition of stomach cancer, including gastroesophageal joint (GEJ) cancer, which forms at the junction of the stomach and esophageal, can be attributed to stomach cancer.
compared with stomach cancer, the prevalence of gastroesophageal cancer is low, but it is on the rise.
source: Shishi Shiguibao.